Literature DB >> 33484964

Corticosteroids and cellulose purification improve, respectively, the in vivo translation and vaccination efficacy of sa-mRNAs.

Zifu Zhong1, Séan McCafferty2, Lisa Opsomer1, Haixiu Wang3, Hanne Huysmans1, Joyca De Temmerman4, Stefan Lienenklaus5, João Paulo Portela Catani1, Francis Combes2, Niek N Sanders6.   

Abstract

Synthetic mRNAs are an appealing platform with multiple biomedical applications ranging from protein replacement therapy to vaccination. In comparison with conventional mRNA, synthetic self-amplifying mRNAs (sa-mRNAs) are gaining interest because of their higher and longer-lasting expression. However, sa-mRNAs also elicit an innate immune response, which may complicate their clinical application. Approaches to reduce the innate immunity of sa-mRNAs have not been studied in detail. Here we investigated, in vivo, the effect of several innate immune inhibitors and a novel cellulose-based mRNA purification approach on the type I interferon (IFN) response and the translation and vaccination efficacy of our formerly developed sa-mRNA vaccine against Zika virus. Among the investigated inhibitors, we found that corticosteroids and especially topical application of clobetasol at the sa-mRNA injection site was the most efficient in suppressing the type I IFN response and increasing the translation of sa-mRNA. However, clobetasol prevented formation of antibodies against sa-mRNA-encoded antigens and should therefore be avoided in a vaccination context. Residual dsRNA by-products of the in vitro transcription reaction are known inducers of immediate type I IFN responses. We additionally demonstrate a drastic reduction of these dsRNA by-products upon cellulose-based purification, reducing the innate immune response and improving sa-mRNA vaccination efficacy.
Copyright © 2021 The American Society of Gene and Cell Therapy. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Zika vaccine; cellulose; clobetasol; innate immunity inhibitors; mRNA purification; self-amplifying mRNA; type I IFN

Mesh:

Substances:

Year:  2021        PMID: 33484964      PMCID: PMC8058483          DOI: 10.1016/j.ymthe.2021.01.023

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  45 in total

Review 1.  Messenger RNA-based vaccines.

Authors:  Steve Pascolo
Journal:  Expert Opin Biol Ther       Date:  2004-08       Impact factor: 4.388

Review 2.  Toll-like receptors.

Authors:  Eva Marie Y Moresco; Diantha LaVine; Bruce Beutler
Journal:  Curr Biol       Date:  2011-07-12       Impact factor: 10.834

3.  Comparison of the Expression Kinetics and Immunostimulatory Activity of Replicating mRNA, Nonreplicating mRNA, and pDNA after Intradermal Electroporation in Pigs.

Authors:  Bregje Leyman; Hanne Huysmans; Séan Mc Cafferty; Francis Combes; Eric Cox; Bert Devriendt; Niek N Sanders
Journal:  Mol Pharm       Date:  2018-01-17       Impact factor: 4.939

Review 4.  Type I interferons (alpha/beta) in immunity and autoimmunity.

Authors:  Argyrios N Theofilopoulos; Roberto Baccala; Bruce Beutler; Dwight H Kono
Journal:  Annu Rev Immunol       Date:  2005       Impact factor: 28.527

Review 5.  Tailoring mRNA Vaccine to Balance Innate/Adaptive Immune Response.

Authors:  Sergio Linares-Fernández; Céline Lacroix; Jean-Yves Exposito; Bernard Verrier
Journal:  Trends Mol Med       Date:  2019-11-05       Impact factor: 11.951

6.  A viral RNA structural element alters host recognition of nonself RNA.

Authors:  Jennifer L Hyde; Christina L Gardner; Taishi Kimura; James P White; Gai Liu; Derek W Trobaugh; Cheng Huang; Marco Tonelli; Slobodan Paessler; Kiyoshi Takeda; William B Klimstra; Gaya K Amarasinghe; Michael S Diamond
Journal:  Science       Date:  2014-01-30       Impact factor: 47.728

7.  Observations on the systemic effect of topical clobetasol propionate (Dermovate).

Authors:  J A Carruthers; P J August; R C Staughton
Journal:  Br Med J       Date:  1975-10-25

8.  Type I Interferons Interfere with the Capacity of mRNA Lipoplex Vaccines to Elicit Cytolytic T Cell Responses.

Authors:  Ans De Beuckelaer; Charlotte Pollard; Sandra Van Lint; Kenny Roose; Lien Van Hoecke; Thomas Naessens; Vimal Kumar Udhayakumar; Muriel Smet; Niek Sanders; Stefan Lienenklaus; Xavier Saelens; Siegfried Weiss; Guido Vanham; Johan Grooten; Stefaan De Koker
Journal:  Mol Ther       Date:  2016-08-10       Impact factor: 11.454

9.  Self-Amplifying RNA Vaccines Give Equivalent Protection against Influenza to mRNA Vaccines but at Much Lower Doses.

Authors:  Annette B Vogel; Laura Lambert; Ekaterina Kinnear; David Busse; Stephanie Erbar; Kerstin C Reuter; Lena Wicke; Mario Perkovic; Tim Beissert; Heinrich Haas; Stephen T Reece; Ugur Sahin; John S Tregoning
Journal:  Mol Ther       Date:  2017-12-05       Impact factor: 11.454

View more
  7 in total

Review 1.  Oral mRNA Vaccines Against Infectious Diseases- A Bacterial Perspective [Invited].

Authors:  Vijayakumar Jawalagatti; Perumalraja Kirthika; John Hwa Lee
Journal:  Front Immunol       Date:  2022-05-03       Impact factor: 8.786

2.  A dual-antigen self-amplifying RNA SARS-CoV-2 vaccine induces potent humoral and cellular immune responses and protects against SARS-CoV-2 variants through T cell-mediated immunity.

Authors:  Sean McCafferty; A K M Ashiqul Haque; Aster Vandierendonck; Brian Weidensee; Magalie Plovyt; Magdalena Stuchlíková; Nathalie François; Sophie Valembois; Leo Heyndrickx; Johan Michiels; Kevin K Ariën; Linos Vandekerckhove; Rana Abdelnabi; Caroline S Foo; Johan Neyts; Itishri Sahu; Niek N Sanders
Journal:  Mol Ther       Date:  2022-04-20       Impact factor: 12.910

3.  Corticosteroids and mRNA Vaccines: A Word of Caution.

Authors:  Zifu Zhong; Francis Combes; Niek N Sanders
Journal:  Mol Ther       Date:  2021-02-03       Impact factor: 11.454

4.  A self-amplifying mRNA SARS-CoV-2 vaccine candidate induces safe and robust protective immunity in preclinical models.

Authors:  Giulietta Maruggi; Corey P Mallett; Jason W Westerbeck; Tiffany Chen; Giuseppe Lofano; Kristian Friedrich; Lin Qu; Jennifer Tong Sun; Josie McAuliffe; Amey Kanitkar; Kathryn T Arrildt; Kai-Fen Wang; Ian McBee; Deborah McCoy; Rebecca Terry; Alison Rowles; Maia Araujo Abrahim; Michael A Ringenberg; Malcolm J Gains; Catherine Spickler; Xuping Xie; Jing Zou; Pei-Yong Shi; Taru Dutt; Marcela Henao-Tamayo; Izabela Ragan; Richard A Bowen; Russell Johnson; Sandra Nuti; Kate Luisi; Jeffrey B Ulmer; Ann-Muriel Steff; Rashmi Jalah; Sylvie Bertholet; Alan H Stokes; Dong Yu
Journal:  Mol Ther       Date:  2022-01-03       Impact factor: 12.910

Review 5.  Regulatory guidelines and preclinical tools to study the biodistribution of RNA therapeutics.

Authors:  P Vervaeke; S E Borgos; N N Sanders; F Combes
Journal:  Adv Drug Deliv Rev       Date:  2022-03-26       Impact factor: 17.873

Review 6.  mRNA vaccines: the most recent clinical applications of synthetic mRNA.

Authors:  Suji Kwon; Minseon Kwon; Seongeun Im; Kyuri Lee; Hyukjin Lee
Journal:  Arch Pharm Res       Date:  2022-04-15       Impact factor: 6.010

Review 7.  Strategies for controlling the innate immune activity of conventional and self-amplifying mRNA therapeutics: Getting the message across.

Authors:  An-Katrien Minnaert; Helena Vanluchene; Rein Verbeke; Ine Lentacker; Stefaan C De Smedt; Koen Raemdonck; Niek N Sanders; Katrien Remaut
Journal:  Adv Drug Deliv Rev       Date:  2021-07-26       Impact factor: 17.873

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.